Osteoarthritis Trial, Recruiting NCT06878417 Sponsor: University Health Network, Toronto Condition: Osteoarthritis
Back to Osteoarthritis

Osteoarthritis Trial, Recruiting

NCT06878417
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People between 40 and 80 years of age
  • People who have been diagnosed with hip and/or knee osteoarthritis according to specific rheumatology guidelines set by the American College of Rheumatology
  • People experiencing a moderate to severe level of pain that interferes with daily life, as measured by a specific pain questionnaire (confirm with trial site for exact score details)
  • People who have not started any new pain medications or osteoarthritis treatments in the past 4 weeks
  • People who are able to read, understand, and self-report in English or French

Who may not be able to join:

  • People who have hip or knee surgery planned within the next 4 months
  • People who have had an injection into the affected joint(s) — such as cortisone or platelet-rich plasma — within the past 3 months
  • People who have a joint injection planned during the trial period
  • People who have an inflammatory type of arthritis, such as rheumatoid arthritis, psoriatic arthritis, or gout
  • People who have medical reasons why they should not take cannabis or cannabinoid-based products
  • People who have used the cannabinoid medications nabilone or nabiximols in the past 30 days
  • People who have used cannabis — whether medical or recreational — in the past 30 days
  • People who have a history of a diagnosed cannabis use disorder or dependence
  • People who currently have an active substance use disorder
  • People who currently have a diagnosis of bipolar disorder, major depression, or psychosis as defined by standard psychiatric guidelines
  • People who have an uncontrolled medical condition or major psychiatric disorder
  • People who are currently taking the blood-thinning medication warfarin
  • People who are known to be pregnant or who are currently breastfeeding
  • People — both men and women — who are planning a pregnancy during the study or within 12 weeks after the study medications are stopped
  • People who do not have a fixed address, or who plan to change address within the next 4 months
  • People who have a known or suspected allergy to palm oil or coconut oil

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Dr. Hance Clarke, MD, University Health Network, Toronto

Phone: 1-416-340-4800

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
29 January 2026
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Feasibility outcome: pertaining to the enrollment rate; Feasibility outcome: pertaining to the Protocol adherence; Feasibility outcome: pertaining to data completeness

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov